PPI in Weaning Prediction
Launched by GAZIOSMANPASA RESEARCH AND EDUCATION HOSPITAL · Aug 6, 2025
Trial Information
Current as of November 06, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a way to help doctors decide when it’s safe to remove patients from mechanical breathing machines in the intensive care unit (ICU). Specifically, it looks at a measurement called the Peripheral Perfusion Index (PPI), which shows how well blood is flowing to the body’s extremities like the fingers. The study aims to see if PPI can better predict whether a patient will do well after the breathing tube is taken out, compared to current methods doctors use.
Patients who have been on a breathing machine for at least two days and are ready to try breathing on their own may be eligible to join. To participate, patients (or their legal representatives) need to agree to be part of the study. Those who are too unstable or have certain blood flow problems in their hands won’t be included. If you join this study, doctors will monitor your PPI along with other usual checks during the trial to help understand if this new measurement can improve the safety and timing of taking patients off ventilators.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who have been on mechanical ventilation for at least 48 hours
- • Patients over 18 years of age who are planned to undergo extubation following a spontaneous breathing trial (SBT)
- • Patients or their legal representatives who provide informed consent to participate in the study
- Exclusion Criteria:
- • Patients for whom extubation is not planned due to hemodynamic instability
- • Patients with peripheral vascular disease or a history of hand surgery
- • Patients who die or cannot be followed up during the study period
About Gaziosmanpasa Research And Education Hospital
Gaziosmanpasa Research and Education Hospital is a leading healthcare institution dedicated to advancing medical research and education. With a commitment to innovative clinical practices, the hospital serves as a hub for clinical trials aimed at improving patient outcomes and enhancing therapeutic options. The institution fosters collaboration among multidisciplinary teams, integrating cutting-edge research with exceptional patient care. By prioritizing ethical standards and regulatory compliance, Gaziosmanpasa Research and Education Hospital is poised to contribute significantly to the field of medical science and the development of new treatment modalities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
İstanbul, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported